Grok AI Market Share Surges as xAI Faces Scrutiny Over Image Generation Controversy 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
Bank of America CEO Brian Moynihan’s 2025 Compensation Rises 17% to $41 Million Amid Strong Profit Growth 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Lockheed Martin Secures $101M in U.S. Defense Contracts for AEGIS, F-35, and Missile Systems 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
Valero Energy Expands Venezuelan Crude Imports as U.S. Sanctions Ease 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Paramount Skydance Appoints Rene Augustine as SVP of Global Public Policy Amid Warner Bros Takeover Battle 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Sachem Head Boosts Warner Bros. Discovery Stake Amid Netflix Deal and Paramount Bid 
RALEIGH, N.C., Nov. 03, 2017 -- INC Research/inVentiv Health (Nasdaq:INCR), the only fully integrated biopharmaceutical solutions organization, today announced that Chief Executive Officer Alistair Macdonald is scheduled to present at the Jefferies 2017 London Healthcare Conference. Mr. Macdonald’s presentation is scheduled for Thursday, November 16, 2017 at 10:00 a.m. GMT.
Links to INC Research/inVentiv Health’s live presentation and archived audio replay, as well as the presentation materials, will be available via the Company’s Investor Relations website at investor.incresearch.com.
About INC Research/inVentiv Health
INC Research/inVentiv Health (Nasdaq:INCR) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to address new market realities where clinical and commercial share expertise, data and insights to accelerate biopharmaceutical performance. With more than 22,000 employees and the ability to support customers in more than 110 countries, our global scale and deep therapeutic alignment enables INC Research/inVentiv Health to help customers successfully navigate an increasingly complex environment. For more information on our Raleigh, N.C.-based company, visit incresearch.com or inventivhealth.com.
| Investor Relations Contact: | Press/Media Contact: | |
| Ronnie Speight | Danielle DeForge | |
| Vice President, Investor Relations | Senior Director, External Communications | |
| +1 919 745 2745 | +1 781 425 2624 | |
| [email protected] | [email protected] |
